

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CK Life Sciences Int'l., (Holdings) Inc.**

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

### **ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES**

The Board wishes to announce the following information in accordance with Rule 13.18 of the Listing Rules.

In compliance with Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"), the board of directors (the "Board") of CK Life Sciences Int'l., (Holdings) Inc. (the "Company") wishes to announce that, on 22nd August, 2011, the Company together with Isnecca Pty Limited, Accensi Pty Ltd, Apil Healthcare Int'l Pty Ltd, Lipa Pharmaceuticals Ltd and Amgrow Pty Limited, all being indirect wholly-owned subsidiaries of the Company, as guarantors and Ample Castle Limited ("Ample"), an indirect wholly-owned subsidiary of the Company, as borrower entered into a facility agreement (the "Agreement") with Commonwealth Bank of Australia, Singapore Branch ("CBA Singapore"), as lender.

Pursuant to the Agreement, CBA Singapore will grant a term loan of HK\$480 million (the "Facility") to Ample for the purpose of loan refinancing. The loan(s) under the Facility shall be repayable on the date which is three years after its drawdown. The Company guarantees the obligations of Ample under the Agreement.

Pursuant to the Agreement, it shall be an event of default if Cheung Kong (Holdings) Limited, being the controlling shareholder of the Company and currently holds approximately 45.31% of the issued share capital of the Company, reduces its direct or indirect shareholding in the Company to less than 44.01% of the issued share capital of the Company, for so long as any amount remains outstanding under the Facility. If an event of default under the Agreement occurs, CBA Singapore may, by notice to Ample, cancel the loan(s) under the Facility and declare that all or part of the loan(s), together with interest accrued thereon and all other amounts accrued or payable under the Agreement to be immediately due and payable.

Disclosure will be included in the interim and annual reports of the Company for so long as the above obligation continues to exist.

By Order of the Board  
**CK Life Sciences Int'l., (Holdings) Inc.**  
**Eirene Yeung**  
*Company Secretary*

Hong Kong, 22nd August, 2011

*As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Chu Kee Hung; and the Non-executive Directors are Mr. Peter Peace Tulloch, Professor Wong Yue-chim, Richard (Independent Non-executive Director), Mrs. Kwok Eva Lee (Independent Non-executive Director) and Mr. Colin Stevens Russel (Independent Non-executive Director).*